Form SCHEDULE 13G/A Theravance Biopharma, Filed by: Newtyn Management, LLC

August 14, 2026 4:23 PM EDT





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  See Item 2 for additional information.


SCHEDULE 13G




Comment for Type of Reporting Person:  See Item 2 for additional information.


SCHEDULE 13G



 
Newtyn Management, LLC
 
Signature:/s/ Eugene Dozortsev
Name/Title:Eugene Dozortsev, Authorized Signatory
Date:08/14/2026
 
Newtyn TE Partners, LP
 
Signature:/s/ Eugene Dozortsev
Name/Title:Eugene Dozortsev, Authorized Signatory of Newtyn Management, LLC, the Investment Manager
Date:08/14/2026
Exhibit Information

1. Joint Filing Agreement, dated August 16, 2024, by and among Newtyn Management, LLC and Newtyn TE Partners, LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on August 16, 2024).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

13G